Loading...
XETR
V3V
Market cap70mUSD
May 19, Last price  
3.96EUR
1D
0.00%
1Q
-2.94%
Jan 2017
-25.42%
IPO
-69.42%
Name

Vita 34 AG

Chart & Performance

D1W1MN
P/E
—
P/S
0.81
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.21%
Rev. gr., 5y
30.44%
Revenues
77m
+11.78%
015,426,00014,957,00015,097,00016,963,00016,001,00013,603,00013,554,00013,786,00014,169,00016,290,00019,186,00020,410,00020,247,00020,070,00028,418,00068,940,00077,062,000
Net income
-2m
L-93.19%
0-1,185,000-1,712,000596,000349,0001,191,000-579,000838,0001,100,0001,979,000408,000-322,000828,0001,350,0001,449,000-3,926,000-27,385,000-1,865,000
CFO
9m
P
-341,000-1,664,000-2,939,0001,149,0001,008,000-683,0002,039,0001,775,0001,055,0002,590,0002,287,0001,530,0004,598,0006,318,0003,980,0002,727,000-4,486,0009,154,000
Dividend
Jun 05, 20190.16 EUR/sh
Earnings
May 29, 2025

Profile

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
URL
https://www.vita34.de/
IPO date
Nov 21, 2007
Employees
815
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
77,062
11.78%
68,940
142.59%
Cost of revenue
66,648
83,670
Unusual Expense (Income)
NOPBT
10,414
(14,730)
NOPBT Margin
13.51%
Operating Taxes
(2,309)
(908)
Tax Rate
NOPAT
12,723
(13,822)
Net income
(1,865)
-93.19%
(27,385)
597.53%
Dividends
(7)
Dividend yield
Proceeds from repurchase of equity
6,997
BB yield
Debt
Debt current
7,808
16,126
Long-term debt
26,876
24,742
Deferred revenue
60,062
46,615
Other long-term liabilities
1,781
3,335
Net debt
17,266
23,119
Cash flow
Cash from operating activities
9,154
(4,486)
CAPEX
(3,409)
(6,431)
Cash from investing activities
(3,574)
(5,811)
Cash from financing activities
(5,088)
(6,273)
FCF
5,553
(6,438)
Balance
Cash
17,416
18,233
Long term investments
2
(484)
Excess cash
13,565
14,302
Stockholders' equity
25,588
(15,275)
Invested Capital
92,628
108,008
ROIC
12.68%
ROCE
9.47%
EV
Common stock shares outstanding
15,881
15,828
Price
Market cap
EV
EBITDA
18,976
(6,180)
EV/EBITDA
Interest
1,726
2,048
Interest/NOPBT
16.57%